Skip to content

Efficacy of adding dexmedetomidine for IPACK in patients undergoing total knee arthroplasty: a randomized controlled trial

Efficacy of adding dexmedetomidine for IPACK in patients undergoing total knee arthroplasty: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080565
Enrollment
Unknown
Registered
2024-02-01
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kneed Osteoarthritis

Interventions

1. Conventional use of IPACK group:Ropivacaine is routinely used for nerve blocks
2. Modified IPACK group with dexmedetomidine:Add dexmedetomidine for nerve block

Sponsors

Xi’an Honghui Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) The age of the patient is 18-100 years old (including the boundary value); (2) The patient requires knee arthroplasty due to knee osteoarthritis.

Exclusion criteria

Exclusion criteria: (1) BMI >30; (2) pain in the knee associated with allergy to the study drug and changes in nerve damage; (3) Ongoing antipsychotic medication, history of bipolar disorder and schizophrenia, and other conditions that the investigator deems unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;Dosage of morphine within 24 h after surgery;Total morphine use during hospitalization;

Secondary

MeasureTime frame
Western Ontario and McMaster University Osteoarthritis Index (WOMAC);Quality of recovery-15 score;Times of sleep interruption due to pain on the night of surgery;Postoperative adverse events;

Countries

China

Contacts

Public ContactLi Zheng

Department of Joint Surgery,Xi’an Honghui Hospital

leezheng08@163.com+86 130 9696 6117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026